BCL2L1 and synovial sarcoma: To conclude, our observations indicate a clear benefit of Bcl-xL inhibition for radiotherapy in HNSCC and synovial sarcoma cell lines, especially in cell lines expressing high Bcl-xL levels and showing Bcl-xL upregulation under irradiation.